



Business Results


First Nine Months of Fiscal Year Ending March 31, 2016

February 3, 2016

Financial Highlights



Net sales and all income categories reached historic highs.



	First nine months of fiscal year ending March 31, 2016	First nine months of fiscal year ended March 31, 2015
1USD	¥121.7	¥106.9
1EUR	¥134.4	¥140.3
1CNY	¥19.3	¥17.4

Copyright by Sysmex Corporation

	First nine months of fiscal year ending March 31, 2016		First nine months of fiscal year ended March 31, 2015		(Billions of yen) YOY (Previous period = 100%)
	Results	Ratio	Results	Ratio	
Net Sales	185.6	100%	155.8	100%	119.1%
Cost of Sales	74.0	39.9%	65.0	41.7%	113.9%
SG&A	69.4	37.4%	59.3	38.1%	117.0%
Operating Income	42.2	22.7%	31.5	20.2%	133.9%
Ordinary Income	41.0	22.1%	33.1	21.3%	123.9%
Profit Attributable to Owners of Parent	27.0	14.6%	20.6	13.2%	131.4%

- **Net sales:** The Company recorded solid double-digit sales growth in all overseas geographic regions, centered on China and EMEA.
- **Operating income:** Operating income rose substantially thanks to the effects of higher sales and yen depreciation (against the U.S. dollar and the Chinese yuan).
- **Non-operating balance:** The forex loss was ¥1.43 billion (¥1.11 billion gain in the previous fiscal year).
- **Extraordinary income:** Extraordinary income amounted to ¥0.96 billion (¥0.05 billion extraordinary loss in the previous fiscal year).

Notes: Exchange rate fluctuations raised net sales ¥7.01 billion and operating income ¥7.93 billion. At the exchange rates prevailing one year earlier, net sales would have been up 14.6% year on year, and operating income up 8.8%.


- **Capital expenditure (tangible):** ¥9.24 billion
- **Depreciation and amortization:** ¥9.13 billion
- **R&D expenditure:** ¥12.57 billion

Breakdown of Net Sales and Operating Income


(Billions of yen)

Net Sales

Note: FX impact excluded from regional sales below



Operating Income



Net Sales by Geographic Region



(Billions of yen)

Net Sales by Geographic Region (Sales to Customers)


	First nine months of fiscal year ending March 31, 2016		First nine months of fiscal year ended March 31, 2015		YOY	(Local currency)
	Results	Ratio	Results	Ratio	(Yen)	
Net Sales	185.6	100%	155.8	100%	119.1%	-
Region	Americas	40.9 22.0%	32.4	20.8%	126.2%	110.9%
	EMEA	51.7 27.9%	46.9	30.1%	110.3%	115.1%
	China	48.4 26.1%	34.6	22.2%	140.0%	126.1%
	AP	13.5 7.3%	11.7	7.5%	115.4%	-
	Japan*	30.9 16.7%	30.1	19.3%	102.8%	-

* Includes sales to IDEXX and other customers

Exchange Rates

	First nine months of fiscal year ending March 31, 2016	First nine months of fiscal year ended March 31, 2015
1USD	¥121.7	¥106.9
1EUR	¥134.4	¥140.3
1CNY	¥19.3	¥17.4

● Percentage of Sales in Emerging Markets



Sales by Business



(Billions of yen)



	First nine months of fiscal year ending March 31, 2016		First nine months of fiscal year ended March 31, 2015		YoY (Previous = 100%)
	Results	Ratio	Results	Ratio	
Hematology	119.5	64.4%	100.5	64.5%	118.9%
Urinalysis	13.5	7.3%	11.8	7.6%	115.0%
Others ¹	1.2	0.7%	0.9	0.6%	132.1%
HU-BU	134.4	72.4%	113.3	72.7%	118.6%
Immunochemistry	4.0	2.2%	2.2	1.5%	178.2%
Clinical Chemistry	2.6	1.5%	2.7	1.8%	97.3%
Hemostasis	31.3	16.9%	23.2	14.9%	134.7%
ICH-BU	38.1	20.5%	28.3	18.2%	134.6%
LS-BU	2.5	1.4%	2.1	1.4%	121.2%
Others²	10.5	5.7%	12.0	7.7%	87.3%
Total Net Sales	185.6	100.0%	155.8	100.0%	119.1%

1. Simple clinical FCM products for emerging markets, etc.

2. Clinical laboratory information systems (formerly included in “Others” in HU-BU), sales of third-party products (formerly included in “Other IVD”), FCM products for research and industry, etc.

Figures for the first nine months of the fiscal year ended March 31, 2015, have been adjusted to align with changes in certain categories from the fiscal year ending March 31, 2016 (“Others” in HU-BU, “HU-BU” and “Others”).

Geographic Segment Information: Americas



* Revision in intragroup transaction prices
Copyright by Sysmex Corporation

(Billions of yen)	First nine months of fiscal year ending March 31, 2016	First nine months of fiscal year ended March 31, 2015	YOY (Previous period = 100%)	
			(Yen basis)	(Local currency basis)
Net Sales	40.9	32.4	126.2%	110.9%
Operating Income*	1.5	1.7	89.0%	78.2%



Note: Excluding the impact of the reversal in deferred service revenue and income in the first three months of the fiscal year ended March 31, 2015, net sales would have been up 27.9% and operating income up 11.1%. (The reversal in deferred service revenue and income in the first three months of the fiscal year ended March 31, 2015, had a ¥0.42 billion positive impact on net sales and a ¥0.36 billion positive impact on operating income.)

- In addition to positive sales of the XN-Series, higher sales in Central and South America led to higher sales for the region.
- Operating income decreased due to a reversal in deferred service revenue and income in the same period of the fiscal year ended March 31, 2015, and a rise in SG&A expenses to strengthen sales and after-sales service activities in the United States

Local Currency Basis

- **United States:** Sales increased due to higher sales of system products in the hematology field through the acquisition of major projects.
- **Central and South America:** Despite the impact of depreciation in the value of the real, sales increased, owing to such factors as the acquisition of a large-scale government project in Mexico.

Geographic Segment Information: EMEA*



*Europe, the Middle East and Africa

(Billions of yen)	First nine months of fiscal year ending March 31, 2016	First nine months of fiscal year ended March 31, 2015	YOY (Previous period = 100%)	
			(Yen basis)	(Local currency basis)
Net Sales	51.7	46.9	110.3%	115.1%
Operating Income*	2.1	4.2	49.9%	52.1%

- **Strong sales in the hematology field throughout the region, including the five major countries, compensated for the impact of yen appreciation.**
- **Operating income fell despite the increase in net sales because of the revision in intragroup transaction prices and increased operating expenses at Partec and Inostics.**



Note: Absent the impact of Partec and Inostics, net sales would have been up 11.1%, and operating income down 14.2%.

Local Currency Basis

- **Five major countries:** Sales were up in all five countries.
- **-Italy:** Large-scale projects pushed up sales, centered on the hematology field.
- **Other parts of Europe:** Sales increased in Denmark due to the acquisition of major projects, and other countries.
- **Eastern Europe, Russia:** Sales increased thanks to expansion in the hematology field in Poland, and in Russia due to the acquisition of a project for a large-scale commercial lab.
- **Middle East, Africa:** Sales increased, helped by higher XN-Series sales in the Middle East.

* Revision in intragroup transaction prices
Copyright by Sysmex Corporation

Geographic Segment Information: China



(Billions of yen)	First nine months of fiscal year ending March 31, 2016	First nine months of fiscal year ended March 31, 2015	YOY (Previous period = 100%)	
			(Yen basis)	(Local currency basis)
Net Sales	48.4	34.6	140.0%	126.1%
Operating Income*	4.9	5.1	95.7%	86.2%

- Strong sales in the hematology, hemostasis, immunochemistry fields pushed up net sales substantially.
- Operating income was down year on year due to the impact of the revision in intragroup transaction prices and higher SG&A expenses to reinforce activities in the immunochemistry field.

Local Currency Basis


- **Hematology:** Sales were up year on year, reflecting increased sales of instruments in the XN-Series, due to favorable system product sales to meet needs for increased testing efficiency.
- **Hemostasis:** Sales of instruments and reagents grew significantly due to favorable sales of the high-end CS-Series and increased sales of fibrin parameter reagents.
- **Urinalysis:** Sales increased, thanks to increased sales of the UF-Series.
- **Immunochemistry:** Sales increased due to expanded sales of the HISCL-Series (commencing in the third quarter of the fiscal year ended March 31, 2015).

* Revision in intragroup transaction prices

Geographic Segment Information: AP



Billions of yen



* Revision in intragroup transaction prices

(Billions of yen)	First nine months of fiscal year ending March 31, 2016	First nine months of fiscal year ended March 31, 2015	YOY (Previous period = 100%) (Yen basis)
Net Sales	13.5	11.7	115.4%
Operating Income*	1.3	1.0	133.6%


- Net sales for the region increased, with higher sales centered on the hematology field in countries including South Korea, Indonesia and India.
- Operating income increased, reflecting higher net sales.

- **Southeast Asia:** Sales increased, centered on higher sales in the hematology field in Indonesia, the Philippines and Vietnam.
- **South Asia:** In addition to sales growth in the hematology and clinical chemistry fields in India, successful efforts against other companies boosted sales in the hematology field in Bangladesh.
- **Oceania:** Despite the acquisition of large-scale hemostasis projects, sales were down, reflecting comparison with the same period of the previous year, when we recorded large-scale projects in Australia.
- **South Korea, Taiwan:** Sales were up due to increased sales in South Korea, centering on hematology instruments and reagents.

Geographic Segment Information: Japan



Billions of yen



(First nine months of years to March 31)

- Intra-Area Transfers: Exports to Group Affiliates, Others
- Sales to Customers: IDEXX and Others
- Sales to Customers: Japan
- Operating Income

(Billions of yen)	First nine months of fiscal year ending March 31, 2016	First nine months of fiscal year ended March 31, 2015	YOY (Previous period = 100%)
Net Sales	102.2	83.9	121.7%
Sales to Customers	30.9	30.1	102.8%
Japan	28.4	28.3	100.2%
IDEX and Others	2.5	1.7	145.6%
Intra-Area Transfers	71.2	53.8	132.2%
Operating Income*	31.3	19.9	156.7%

● **Although growth in Japan was flat, intra-area transfers to Group affiliates (overseas) pushed up internal sales, and the region benefited from the impact of a revision in intragroup transaction prices, pushing up net sales and operating income.**

- **Japan:** Although instrument sales decreased, reagent sales were up in the hematology, hemostasis and immunochemistry fields, leading to flat sales growth.
- **IDEXX and others:** Sales were up, thanks to robust sales of instruments for IDEXX.

* Impact of the revision in intragroup transaction prices

Copyright by Sysmex Corporation

Consolidated Earnings Forecast

No changes subsequent to November 2015 revisions



Consolidated Earnings forecast for the Fiscal Year Ending March 31, 2016

Net Sales: ¥252.0 billion Operating Income: ¥52.0 billion Ordinary Income: ¥51.4 billion Profit Attributable to Owners of Parent*: ¥33.0 billion


Operating Margin: 20.6% Ordinary Margin: 20.4% Profit Attributable to Owners of Parent to Net Sales: 13.1%

Planned Investment

Capital Expenditure: ¥16.0 billion Depreciation and Amortization: ¥12.4 billion R&D Expenditure: ¥16.2 billion

	Assumed exchange rates for full year	Actual for fiscal year ended March 31, 2015
1USD	¥118.4	¥109.9
1EUR	¥132.5	¥138.8
1CNY	¥19.0	¥17.8


	Exchange rate sensitivity of net sales (year)	Exchange rate sensitivity of operating income (year)
USD	¥0.45 billion	¥0.41 billion
EUR	¥0.35 billion	¥0.19 billion
CNY	¥3.40 billion	¥0.28 billion



Note: Figures shown for fiscal years ended on or before March 31, 2015 are "net income."

Financial Targets: Sales and Operating Income by Region

No changes subsequent to November 2015 revisions



Start of the Voluntary Adoption of IFRS



- Sysmex will begin the voluntary adoption of IFRS for its consolidated financial statements from the fiscal year ending March 31, 2017.
- We will begin disclosure based on IFRS from the first quarter of the fiscal year ending March 31, 2017.

	Fiscal year ending March 31, 2016 (May 2016 announcement)	First quarter of the fiscal year ending March 31, 2017 (August 2016 announcement)
Operating results	Japanese standards	IFRS Note: Year-on-year comparisons will also be disclosed according to IFRS.
Forecasts	<u>Full year ending March 31, 2017</u> - Japanese standards - IFRS	IFRS

We Believe the Possibilities.

Forward-Looking Statements

This material contains forward-looking statements about Sysmex Corporation and its Group companies (the Sysmex Group). These forward-looking statements are based on the current judgments and assumptions of the Sysmex Group in light of the information currently available to it. Uncertainties inherent in such judgments and assumptions, the future course of our business operations and changes in operating environments both in Japan and overseas may cause our actual results, performance, achievements, or financial position to be materially different from any future results, performance, achievements or financial position either expressed or implied within these forward-looking statements.

Sysmex Corporation

Contact:

IR & Corporate Communication Dept.
Corporate Communication Div.

Phone: +81-78-265-0500

Email: info@sysmex.co.jp

www.sysmex.co.jp/en